Dear Chandler Project,
We at QED know that this is a challenging time for all families. We hope that you are all doing well, are safe, and are using this time to ensure the safety and well-being of your loved ones.
We are actively assessing the impact that COVID-19 may have on our work and we want to assure you that we are committed to moving forward with our program to develop infigratinib as an option for children with achondroplasia. But we also must acknowledge that we are facing unforeseen challenges with this global pandemic.
COVID-19 may cause some delays in our studies that we are hope are temporary as physicians focus on fighting the virus and families stay away from hospitals for non-essential care. We remain hopeful that the clinical trial for infigratinib in achondroplasia can start in the near future, with the exact timing dependent on how this dynamic situation evolves. Our commitment is to conduct our studies in children with achondroplasia at a safe and appropriate time.
We remain committed to the achondroplasia community and, first and foremost, to the safety of any child who participates in our studies. We will keep you up to date as the situation evolves and inform you of key developments from QED.
In the meantime, we wish you well. Please stay safe.
We invite you to read a message from Neil Kumar, the CEO of BridgeBio, the parent company of QED:
An Open Letter To Patients And Their Families From BridgeBio Pharma CEO Neil Kumar
The rapid spread of COVID-19 globally has led to tremendous disruption in the health care industry. We are actively assessing the impact the virus will have on our work at BridgeBio, including the timing of our clinical trials. We are doing our absolute best to minimize any delays, but we know that right now health care institutions and doctors around the world have shifted their focus to emergent COVID-19 cases. Many hospitals and physicians have postponed elective medical procedures and delayed the start of new clinical trials. There is disruption across the country and globe as people are ordered to stay home to slow the spread of the virus. We support these steps, which are needed to minimize the devastating impact of this global pandemic.
Please know that despite these new hurdles we all face, our commitment to patients and their families does not change. That commitment is the cornerstone of our mission at BridgeBio. We exist to bring meaningful medicines to patients as quickly and as safely as possible. But we do have to work within the new reality that is emerging. We are looking at the rapidly changing healthcare landscape on an hour-by-hour basis and trying to minimize disruption to our programs as much as possible.
We are in this together. There will inevitably be delays and we don’t know what the future holds, but we will not stop working as fast as we possibly and safely can for patients. You have our word.
If you would like further information or have questions, please contact us at email@example.com